Dokumendiregister | Terviseamet |
Viit | 11.2-4/24/4882-1 |
Registreeritud | 07.05.2024 |
Sünkroonitud | 08.05.2024 |
Liik | Sissetulev dokument |
Funktsioon | 11.2 Turustamise eelne järelevalve (pre-marketing surveillance) |
Sari | 11.2-4 Erandid vastavushindamismenetlusest, taotlused ja kirjavahetus |
Toimik | 11.2-4/2024 |
Juurdepääsupiirang | Avalik |
Juurdepääsupiirang | |
Adressaat | European Commission |
Saabumis/saatmisviis | European Commission |
Vastutaja | Maarika Ojala (TA, Peadirektori asetäitja (1) vastutusvaldkond, Meditsiiniseadmete osakond) |
Originaal | Ava uues aknas |
From: PISCOI Paul <[email protected]>
Sent: Mon, 06 May 2024 12:06:04 +0000
To: "Medical Devices - IMA" <[email protected]>; "[email protected]" <[email protected]>; "Noelle THEBAULT ([email protected])" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; TAMARIT BARRULL Anna <[email protected]>; TRIPOLI Dean <[email protected]>; MAKSAN Filip <[email protected]>; CALLIGARO Gabriele <[email protected]>; ROCHE Jean-Francois <[email protected]>; FINUCANE Mairead <[email protected]>; ORLANDI Maria Chiara <[email protected]>; PHILIPPE Maya <[email protected]>; ALKHAYAT Nada <[email protected]>; TKACHENKO Olga <[email protected]>; VANHOECK Valerie <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "Zajac; Boris ([email protected])" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; Gearóid McGauran ([email protected]) <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>
Cc: "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "[email protected]" <[email protected]>; "DALY Orla" <[email protected]>; YASSIN Hanim <[email protected]>
Subject: [SUSPICIOUS URL INSIDE]RE: Question regarding use of Pediatric IPG-Medtronic for individual patients.
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. |
Dear all,
I am not sure what contacts list is this one, I presume it is the vigilance, but I just wish to flag that there is a specific working group, e-mailing list, CIRCABC space, including a monitoring file, for the exchanges on derogations.
If you don’t have access please find your national contact in the attached list.
Best regards,
Paul
From: Medical Devices - IMA <[email protected]>
Sent: Monday, May 6, 2024 12:55 PM
To: [email protected]; Noelle THEBAULT ([email protected]) <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; TAMARIT BARRULL Anna (SANTE) <[email protected]>; TRIPOLI Dean (SANTE) <[email protected]>; MAKSAN Filip (ENER) <[email protected]>;
CALLIGARO Gabriele (SANTE) <[email protected]>; ROCHE Jean-Francois (SANTE) <[email protected]>; FINUCANE Mairead (SANTE) <[email protected]>; ORLANDI Maria Chiara (SANTE) <[email protected]>; PHILIPPE
Maya (SANTE) <[email protected]>; ALKHAYAT Nada (SANTE) <[email protected]>; TKACHENKO Olga (SANTE) <[email protected]>; PISCOI Paul (SANTE) <[email protected]>; VANHOECK Valerie (SANTE) <[email protected]>; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; Zajac, Boris ([email protected]) <[email protected]>; [email protected]; [email protected]; [email protected]; [email protected]; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]; [email protected]; [email protected]; Gearóid McGauran ([email protected]) <[email protected]>; [email protected];
[email protected]; [email protected]; [email protected]; [email protected]
Cc: [email protected]; [email protected]; [email protected]; [email protected]
Subject: FW: Question regarding use of Pediatric IPG-Medtronic for individual patients.
Dear Ana Mª Villarta Aguilera and other colleagues,
Please use the email address [email protected] for all inquiries on medical devices.
The Icelandic Medicines Agency has not received derogation request for Pediatric IPG.
Best regards,
Halldóra Þorgilsdóttir
|
Lyfjastofnun | Icelandic Medicines Agency
Vínlandsleið 14 | 113 Reykjavík
Ísland | Iceland
(+354) 520 2100 |
From:
[email protected] <[email protected]>
Sent: þriðjudagur, 30. apríl 2024 12:00
To: [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected]; [email protected];
[email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected]; Lyfjastofnun - IMA <[email protected]>; Valgerður Guðrún Gunnarsdóttir - IMA <[email protected]>;
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected];
[email protected]; [email protected];
[email protected];
[email protected];
[email protected];
[email protected];
[email protected]
Cc: [email protected];
[email protected];
[email protected];
[email protected]
Subject: Question regarding use of Pediatric IPG-Medtronic for individual patients.
Algunos contactos que recibieron este mensaje no suelen recibir correos electrónicos de [email protected]. Por qué esto es importante |
Dear colleagues,
The Spanish Agency (AEMPS) has authorised for two individual patients (March 2023 and March 2024) under Article 59 of the MDR the use of a specially modified pediatric-sized implantable pulse generator, called the Pediatric IPG, which includes a Medtronic Micra sub-assembly (CE marked device) that connects to an epicardial lead. While this makes the leadless pacemaker into one that uses leads, the resulting IPG is significantly smaller than any commercially available pacemaker previously on the market. We were informed by the clinical site that there are no CE marked alternatives for this paediatrics patients.
We have received lately a new application for another patient and we have asked Medtronic about their planning for CE marking and the development of a clinical investigation.
Medtronic states that their plan is to seek market approval in the US first because it seems that they can use real-world evidence from the US implants to support a case for device safety and effectiveness and allow a path to commercialization without a clinical trial in the US. They expect to have the FDA approval in 2 years. After commercialization in the US, they hope to use the information from use in the US to support applications in Europe and other countries. This is a multi-year plan, due to the very small patient population, and the very poor ROI associated with Pediatric IPG.
In the last request there was this information below on the use of the device so it seems that it was only used in Italy and Spain in Europe:
41 devices have been deployed globally: 36 in the US, 3 in Canada, 1 in Italy, and 2 in Spain.
As it seems they do not plan performing clinical investigation in Europe and they want to use compassionate use for the FDA authorization, we would like to know if anyone, beyond Italy, has received an application for derogation for this product or if you have any information or opinion in this regards.
Thank you very much for your help with this, we really appreciate it.
Kind regards,
Ana Mª Villarta Aguilera
Jefa de servicio / Head of service
Área de Investigaciones clínicas / Clinical investigations Area
Departamento de Productos Sanitarios / Medical Devices Department
_________________________________
Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
(+34) 918225440
Calle Campezo 1 · Edificio 8 · E-28022 Madrid · España
CONFIDENCIALIDAD. El contenido de este mensaje y el de cualquier documentación anexa es confidencial y va dirigido únicamente al destinatario del mismo. Si Usted no es el destinatario, le
solicitamos que nos lo indique, no comunique su contenido a terceros y proceda a su destrucción.
CONFIDENTIALITY. The content of this message and any attached information is confidential and exclusively for the use of the addresser. If you are not the addresser, we ask you to notify to the sender, do not pass its content and delete the original.